Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 10.53 AUD 3.54% Market Closed
Market Cap: 1.3B AUD

Intrinsic Value

The intrinsic value of one NEU stock under the Base Case scenario is 6.63 AUD. Compared to the current market price of 10.53 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NEU Intrinsic Value
6.63 AUD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Neuren Pharmaceuticals Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
NEU
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for NEU cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Neuren Pharmaceuticals Ltd
ASX:NEU
AU
Pharmaceuticals
Market Cap
1.3B AUD
IPO
Feb 3, 2005
AU
Pharmaceuticals
Market Cap
1.3B AUD
IPO
Feb 3, 2005
Price
AU$false
EPS
AU$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.

Bull Theses

Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.

Show More Less
How do you feel about NEU?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Neuren Pharmaceuticals Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd

Current Assets 399.3m
Cash & Short-Term Investments 222.2m
Receivables 175.7m
Other Current Assets 1.4m
Non-Current Assets 10.4m
PP&E 31k
Other Non-Current Assets 10.3m
Efficiency

Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Neuren Pharmaceuticals Ltd

Revenue
224.3m AUD
Operating Expenses
-37.7m AUD
Operating Income
186.6m AUD
Other Expenses
-44.5m AUD
Net Income
142m AUD
Fundamental Scores

NEU Profitability Score
Profitability Due Diligence

Neuren Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Exceptional ROIC
64/100
Profitability
Score

Neuren Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

NEU Solvency Score
Solvency Due Diligence

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 26.22 AUD with a low forecast of 20.2 AUD and a high forecast of 32.34 AUD.

Lowest
Price Target
20.2 AUD
92% Upside
Average
Price Target
26.22 AUD
149% Upside
Highest
Price Target
32.34 AUD
207% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Neuren Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NEU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NEU Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one NEU stock?

The intrinsic value of one NEU stock under the Base Case scenario is 6.63 AUD.

Is NEU stock undervalued or overvalued?

Compared to the current market price of 10.53 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 37%.

Back to Top